Overview: Anti-Neutrophil Cytoplasmic Antibody (ANCA) IgG/IgA Rapid TestIntroduction: The Anti-Neutrophil Cytoplasmic Antibody (ANCA) IgG/IgA Rapid Test is a diagnostic tool designed to detect ANCA IgG/IgA antibodies in serum, whole blood, or saliva samples, facilitating the screening of vasculitis. Associated with systemic inflammation of blood vessels, this autoimmune condition presents with fatigue, joint pain, and severe complications like kidney failure if untreated, particularly in older adults or those with autoimmune diseases. Per the 2023 American College of Rheumatology guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in rheumatology clinics. This rapid diagnostic falls under immunology and targets individuals with systemic symptoms, addressing the challenge of early detection to guide immunosuppressive therapy like cyclophosphamide. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing organ damage. Its multi-sample capability enhances its utility.Other Names: ANCA IgG/IgA Rapid Test.FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Inova Diagnostics, this test advanced vasculitis detection, providing a rapid alternative to immunofluorescence with a focus on IgG/IgA.Purpose: The test screens for ANCA IgG/IgA to guide vasculitis diagnosis, assess disease activity, and inform treatment and prevention strategies.Test Parameters: Presence of ANCA IgG/IgA Antibody, detected with reasonable specificity to indicate autoimmune activity, typically detectable in serum or blood during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fatigue, joint pain, or kidney issues.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile SST or EDTA tubes/containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antibody integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade antibodies, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fatigue, joint pain, rash, or prior vasculitis diagnosis, as well as any family history of autoimmune diseases or recent infections.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated vasculitis including kidney failure, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent infections can affect results. Correlation with PR3/MPO or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive result indicates possible vasculitis, necessitating further investigation like PR3/MPO or rheumatology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during inactive disease.Specialist Consultation: Rheumatologists or nephrologists should be consulted for case management, treatment planning, and coordination with autoimmune disease programs.Additional Supporting Tests: PR3, MPO, or biopsy for confirmation.Test Limitations: The test may produce false positives in other autoimmune conditions or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: ACR Guidelines 2023, Arthritis and Rheumatism 2024, Immunology 2025.